EP2763984 - 1-PYRAZOLYL-3-(4-((2-ANILINOPYRIMIDIN-4-YL)OXY)NAPTHTHALEN-1-YL)UREAS AS P38 MAP KINASE INHIBITORS [Right-click to bookmark this link] | |||
Former [2014/33] | 1-PYRAZOLYL-3- (4- ( (2 -ANILINOPYRIMIDIN- 4 - YL) OXY) NAPTHTHALEN- 1 - YL) UREAS AS P38 MAP KINASE INHIBITORS | ||
[2015/46] | Status | No opposition filed within time limit Status updated on 24.02.2017 Database last updated on 03.09.2024 | Most recent event Tooltip | 10.07.2020 | Lapse of the patent in a contracting state New state(s): IS | published on 12.08.2020 [2020/33] | Applicant(s) | For all designated states Respivert Limited 50-100 Holmers Farm Way High Wycombe, Buckinghamshire HP12 4EG / GB | [2014/33] | Inventor(s) | 01 /
ITO, Kazuhiro c/o Respivert Limited Imperial College BioIncubator Level 1 Bessemer Building Imperial College London SW7 2AZ / GB | 02 /
CHARRON, Catherine Elisabeth c/o Respivert Limited Imperial College BioIncubator Level 1 Bessemer Building Imperial College London SW7 2AZ / GB | 03 /
KING-UNDERWOOD, John Moorend Cottage School Lane Pendock Worcestershire GL19 3PW / GB | 04 /
ONIONS, Stuart Thomas c/o Sygnature Chemical Services Ltd Biocity Nottingham Pennyfoot Street Nottingham NG1 1GF / GB | 05 /
LONGSHAW, Alistair Ian c/o Sygnature Chemical Services Ltd Biocity Nottingham Pennyfoot Street Nottingham Nottinghamshire NG1 1GF / GB | 06 /
BROECKX, Rudy c/o Janssen Pharmaceutica NV Turnhoutseweg 30 B-2340 Beerse / BE | 07 /
FILLIERS, Walter c/o Janssen Pharmaceutica NV Turnhoutseweg 30 B-2340 Beerse / BE | 08 /
COPMANS, Alex c/o Janssen Pharmaceutica NV Turnhoutseweg 30 B-2340 Beerse / BE | [2014/33] | Representative(s) | Teuten, Andrew John Sagittarius IP Marlow International Parkway Marlow SL7 1YL / GB | [N/P] |
Former [2014/33] | Teuten, Andrew John Sagittarius IP Three Globeside Fieldhouse Lane Marlow, Buckinghamshire SL7 1HZ / GB | Application number, filing date | 12772383.1 | 03.10.2012 | [2016/16] | WO2012GB52445 | Priority number, date | EP20110183682 | 03.10.2011 Original published format: EP 11183682 | EP20110183688 | 03.10.2011 Original published format: EP 11183688 | EP20120168396 | 16.05.2012 Original published format: EP 12168396 | EP20120168395 | 16.05.2012 Original published format: EP 12168395 | [2014/33] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2013050757 | Date: | 11.04.2013 | Language: | EN | [2013/15] | Type: | A1 Application with search report | No.: | EP2763984 | Date: | 13.08.2014 | Language: | EN | The application published by WIPO in one of the EPO official languages on 11.04.2013 takes the place of the publication of the European patent application. | [2014/33] | Type: | B1 Patent specification | No.: | EP2763984 | Date: | 20.04.2016 | Language: | EN | [2016/16] | Search report(s) | International search report - published on: | EP | 11.04.2013 | Classification | IPC: | C07D403/12, A61K31/4155, A61K31/506, C07D491/10 | [2014/33] | CPC: |
C07D403/12 (EP,CN,KR,US);
A61K31/215 (US);
A61K31/351 (US);
A61K31/4155 (US);
A61K31/506 (KR,US);
A61K31/513 (US);
A61K9/0073 (KR);
A61P1/04 (EP);
A61P1/18 (EP);
A61P11/00 (EP,KR);
A61P11/02 (EP);
A61P11/06 (EP);
A61P17/00 (EP);
A61P17/02 (EP);
A61P17/06 (EP);
A61P19/02 (EP);
A61P27/02 (EP);
A61P27/14 (EP);
A61P29/00 (EP);
A61P3/10 (EP);
A61P31/12 (EP);
A61P31/14 (EP,KR);
A61P35/00 (EP);
A61P35/04 (EP);
A61P37/08 (EP);
A61P43/00 (EP);
A61P7/00 (EP);
A61P9/04 (EP);
C07D491/10 (EP,US);
A61K9/0075 (EP);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2014/33] | Extension states | BA | 07.04.2014 | ME | 07.04.2014 | Title | German: | 1-PYRAZOLYL-3-(4-((2-ANILINOPYRIMIDIN-4-YL)OXY)NAPTHTHALEN-1-YL)HARNSTOFFE ALS P38-MAP-KINASEHEMMER | [2015/46] | English: | 1-PYRAZOLYL-3-(4-((2-ANILINOPYRIMIDIN-4-YL)OXY)NAPTHTHALEN-1-YL)UREAS AS P38 MAP KINASE INHIBITORS | [2015/46] | French: | 1-PYRAZOLYL-3-(4-((2-ANILINOPYRIMIDIN-4-YL)OXY)NAPTHTHALEN-1-YL)URÉES COMME INHIBITEURS DE P38 MAP KINASE | [2015/46] |
Former [2014/33] | 1-PYRAZOLYL-3- (4-((2 -ANILINOPYRIMIDIN-4-YL-)OXY-)NAPTHTHALEN-1-)YL-HARNSTOFFE ALS P38-MAP-KINASEHEMMER | ||
Former [2014/33] | 1-PYRAZOLYL-3- (4- ( (2 -ANILINOPYRIMIDIN- 4 - YL) OXY) NAPTHTHALEN- 1 - YL) UREAS AS P38 MAP KINASE INHIBITORS | ||
Former [2014/33] | L-PYRAZOLYL-3-(4-((2-ANILINOPYRIMIDIN-4-YL)OXY)NAPHTALÉN-1-YL)URÉES EN TANT QU'INHIBITEURS DE P38 MAP KINASE | Entry into regional phase | 07.04.2014 | National basic fee paid | 07.04.2014 | Designation fee(s) paid | 07.04.2014 | Examination fee paid | Examination procedure | 26.07.2013 | Request for preliminary examination filed International Preliminary Examining Authority: EP | 07.04.2014 | Examination requested [2014/33] | 20.06.2014 | Amendment by applicant (claims and/or description) | 02.06.2015 | Communication of intention to grant the patent | 29.09.2015 | Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO | 05.11.2015 | Communication of intention to grant the patent | 23.02.2016 | Fee for grant paid | 23.02.2016 | Fee for publishing/printing paid | 23.02.2016 | Receipt of the translation of the claim(s) | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 02.06.2015 | Opposition(s) | 23.01.2017 | No opposition filed within time limit [2017/13] | Fees paid | Renewal fee | 14.10.2014 | Renewal fee patent year 03 | 12.10.2015 | Renewal fee patent year 04 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | HU | 03.10.2012 | AL | 20.04.2016 | BG | 20.04.2016 | CY | 20.04.2016 | CZ | 20.04.2016 | EE | 20.04.2016 | HR | 20.04.2016 | LT | 20.04.2016 | LV | 20.04.2016 | MK | 20.04.2016 | RO | 20.04.2016 | RS | 20.04.2016 | SI | 20.04.2016 | SK | 20.04.2016 | SM | 20.04.2016 | NO | 20.07.2016 | IS | 20.08.2016 | MT | 31.10.2016 | [2020/33] |
Former [2018/46] | HU | 03.10.2012 | |
AL | 20.04.2016 | ||
BG | 20.04.2016 | ||
CY | 20.04.2016 | ||
CZ | 20.04.2016 | ||
EE | 20.04.2016 | ||
HR | 20.04.2016 | ||
LT | 20.04.2016 | ||
LV | 20.04.2016 | ||
MK | 20.04.2016 | ||
RO | 20.04.2016 | ||
RS | 20.04.2016 | ||
SI | 20.04.2016 | ||
SK | 20.04.2016 | ||
SM | 20.04.2016 | ||
NO | 20.07.2016 | ||
MT | 31.10.2016 | ||
Former [2018/38] | HU | 03.10.2012 | |
BG | 20.04.2016 | ||
CY | 20.04.2016 | ||
CZ | 20.04.2016 | ||
EE | 20.04.2016 | ||
HR | 20.04.2016 | ||
LT | 20.04.2016 | ||
LV | 20.04.2016 | ||
MK | 20.04.2016 | ||
RO | 20.04.2016 | ||
RS | 20.04.2016 | ||
SI | 20.04.2016 | ||
SK | 20.04.2016 | ||
SM | 20.04.2016 | ||
NO | 20.07.2016 | ||
MT | 31.10.2016 | ||
Former [2018/31] | HU | 03.10.2012 | |
CY | 20.04.2016 | ||
CZ | 20.04.2016 | ||
EE | 20.04.2016 | ||
HR | 20.04.2016 | ||
LT | 20.04.2016 | ||
LV | 20.04.2016 | ||
MK | 20.04.2016 | ||
RO | 20.04.2016 | ||
RS | 20.04.2016 | ||
SI | 20.04.2016 | ||
SK | 20.04.2016 | ||
SM | 20.04.2016 | ||
NO | 20.07.2016 | ||
MT | 31.10.2016 | ||
Former [2018/28] | HU | 03.10.2012 | |
CZ | 20.04.2016 | ||
EE | 20.04.2016 | ||
HR | 20.04.2016 | ||
LT | 20.04.2016 | ||
LV | 20.04.2016 | ||
MK | 20.04.2016 | ||
RO | 20.04.2016 | ||
RS | 20.04.2016 | ||
SI | 20.04.2016 | ||
SK | 20.04.2016 | ||
SM | 20.04.2016 | ||
NO | 20.07.2016 | ||
Former [2017/37] | CZ | 20.04.2016 | |
EE | 20.04.2016 | ||
HR | 20.04.2016 | ||
LT | 20.04.2016 | ||
LV | 20.04.2016 | ||
RO | 20.04.2016 | ||
RS | 20.04.2016 | ||
SI | 20.04.2016 | ||
SK | 20.04.2016 | ||
SM | 20.04.2016 | ||
NO | 20.07.2016 | ||
Former [2017/11] | CZ | 20.04.2016 | |
EE | 20.04.2016 | ||
HR | 20.04.2016 | ||
LT | 20.04.2016 | ||
LV | 20.04.2016 | ||
RO | 20.04.2016 | ||
RS | 20.04.2016 | ||
SK | 20.04.2016 | ||
SM | 20.04.2016 | ||
NO | 20.07.2016 | ||
Former [2017/10] | CZ | 20.04.2016 | |
EE | 20.04.2016 | ||
HR | 20.04.2016 | ||
LT | 20.04.2016 | ||
LV | 20.04.2016 | ||
RO | 20.04.2016 | ||
RS | 20.04.2016 | ||
SK | 20.04.2016 | ||
NO | 20.07.2016 | ||
Former [2017/09] | CZ | 20.04.2016 | |
EE | 20.04.2016 | ||
HR | 20.04.2016 | ||
LT | 20.04.2016 | ||
LV | 20.04.2016 | ||
RO | 20.04.2016 | ||
RS | 20.04.2016 | ||
NO | 20.07.2016 | ||
Former [2016/50] | HR | 20.04.2016 | |
LT | 20.04.2016 | ||
LV | 20.04.2016 | ||
RS | 20.04.2016 | ||
NO | 20.07.2016 | ||
Former [2016/46] | LT | 20.04.2016 | |
NO | 20.07.2016 | Cited in | International search | [X]WO03072569 (BOEHRINGER INGELHEIM PHARMA [US]) [X] 1-16 * claims 1-13 *; | [Y]WO2010067130 (RESPIVERT LTD, et al) [Y] 1-16 * claims 1-19 *; | [Y]WO2010067131 (RESPIVERT LTD [GB], et al) [Y] 1-16 * claims 1-22 *; | [Y]WO2010112936 (RESPIVERT LTD [GB], et al) [Y] 1-16 * claims 1-9 *; | [Y]WO2011070368 (RESPIVERT LTD [GB], et al) [Y] 1-16* claims 1-25 *; | [XP]WO2011158039 (RESPIVERT LTD [GB], et al) [XP] 1-16 * claims 1-21 *; | [XP]WO2011158042 (RESPIVERT LTD [GB], et al) [XP] 1-16 * claims 1-38 * | by applicant | WO2010067130 | WO2010112936 | WO2011070369 | WO2011158042 | WO2011158039 | - O'KEEFE, S.J. ET AL., J. BIOL. CHEM., (2007), vol. 282, no. 48, pages 34663 - 71 | - FITZSIMMONS, B.L. ET AL., NEUROREPORT, (2010), vol. 21, no. 4, pages 313 - 7 | - PETTUS, L.H.; WURZ, R.P., CURR. TOP. MED. CHEM., (2008), vol. 8, no. 16, pages 1452 - 67 | - SHMUELI, O. ET AL., COMPTES RENDUS BIOLOGIES, (2003), vol. 326, no. 10-11, pages 1067 - 1072 | - SMITH, S. J., BR. J. PHARMACOL., (2006), vol. 149, pages 393 - 404 | - HALE, K. K., J. IMMUNOL., (1999), vol. 162, no. 7, pages 4246 - 52 | - WANG, X. S. ET AL., J. BIOL. CHEM., (1997), vol. 272, no. 38, pages 23668 - 23674 | - COURT, N. W. ET AL., J. MOL. CELL. CARDIOL., (2002), vol. 34, no. 4, pages 413 - 26 | - MERTENS, S. ET AL., FEBS LETT., (1996), vol. 383, no. 3, pages 273 - 6 | - KUMA, Y., J. BIOL. CHEM., (2005), vol. 280, pages 19472 - 19479 | - CHUNG, F., CHEST, (2011), vol. 139, no. 6, pages 1470 - 1479 | - SMITH, S.J., BR. J. PHARMACOL., (2006), vol. 149, pages 393 - 404 | - UNDERWOOD, D.C. ET AL., AM. J. PHYSIOL., (2000), vol. 279, pages 895 - 902 | - NATH, P. ET AL., EUR. J. PHARMACOL., (2006), vol. 544, pages 160 - 167 | - IRUSEN, E. ET AL., J. ALLERGY CLIN. IMMUNOL., (2002), vol. 109, pages 649 - 657 | - LEE, M.R.; DOMINGUEZ, C., CURRENT MED. CHEM., (2005), vol. 12, pages 2979 - 2994 | - MERCADO, N. ET AL., MOL. PHARMACOL., (2011), vol. 80, no. 6, pages 1128 - 1135 | - PAPADOPOULOS, N.G.; PAPI, A.; PSARRAS, S.; JOHNSTON, S.L., PAEDIATR. RESPIR. REV, (2004), vol. 5, no. 3, pages 255 - 260 | - GRUNBERG, K.; SHARON, R.F. ET AL., AM. J. RESPIR. CRIT. CARE MED., (2001), vol. 164, no. 10, pages 1816 - 1822 | - WAT, D.; GELDER, C. ET AL., J. CYST. FIBROS, (2008), vol. 7, pages 320 - 328 | - LIU, M; WORLEY, S. ET AL., TRANSPL. INFECT. DIS, (2009), vol. 11, no. 4, pages 304 - 312 | - MESSAGE, S.D; LAZA-STANCA, V. ET AL., PNAS, (2008), vol. 105, no. 36, pages 13562 - 13567 | - GERNA, G.; PIRALLA, A. ET AL., J. MED. VIROL, (2009), vol. 81, no. 8, pages 1498 - 1507 | - OLIVER, B.G.; LIM, S. ET AL., THORAX, (2008), vol. 63, pages 519 - 525 | - WANG, J.H.; KWON, H.J.; YONG, J.J., THE LARYNGOSCOPE, (2009), vol. 119, no. 7, pages 1406 - 1411 | - PELEG, A.Y.; WEERARATHNA, T. ET AL., DIABETES METAB. RES. REV., (2007), vol. 23, no. 1, pages 3 - 13 | - KORNUM, J.B.; REIMAR, W. ET AL., DIABETES CARE, (2008), vol. 31, no. 8, pages 1541 - 1545 | - LUDWIG, S, SIGNAL TRANSDUCTION, (2007), vol. 7, pages 81 - 88 | - SHIN, Y.K.; LIU, Q. ET AL., J. GEN. VIROL., (2007), vol. 88, pages 13 - 18 | - EHRHARDT, C.; MARJUKI, H. ET AL., CELL MICROBIOL., (2006), vol. 8, pages 1336 - 1348 | - LUDWIG, S.; WOLFF, T. ET AL., FEBS LETT., (2004), vol. 561, no. 1-3, pages 37 - 43 | - SANDERSON, M.P.; LAU, C.W. ET AL., INFLAMM. ALLERGY DRUG TARGETS, (2009), vol. 8, pages 87 - 95 | - LAU, C. ET AL., J. LMMUNOL., (2008), vol. 180, no. 2, pages 870 - 880 | - BENTLEY, J.K.; NEWCOMB, D.C., J. VIROL., (2007), vol. 81, pages 1186 - 1194 | - INOUE, D.; YAMAYA, M., RESPIR. PHYSIOL. NEUROBIOL., (2006), vol. 154, no. 3, pages 484 - 499 | - SCHREIBER, S. ET AL., CLIN. GASTRO. HEPATOLOGY, (2006), vol. 4, pages 325 - 334 | - SHILO, Y., NATURE REVIEWS CANCER, (2003), vol. 3, pages 155 - 168 | - OLAHARSKY, A.J. ET AL., PLOS COMPUT. BIOL., (2009), vol. 5, no. 7, page E1000446 | - TIGHE, A. ET AL., BMC CELL BIOLOGY, (2007), vol. 8, page 34 | - PARGELLIS, C. ET AL., NATURE STRUCT. BIOL., (2002), vol. 9, no. 4, pages 268 - 272 | - FABIAN, M.A. ET AL., NATURE BIOTECHNOL., (2005), vol. 23, pages 329 - 336 | - MUEHLBAUER P.A.; SCHULER M.J., MUTATION RESEARCH, (2003), vol. 537, pages 117 - 130 | - MEDICHERLA S. ET AL., J. PHARMACOL. EXP. THER., (2008), vol. 324, no. 3, pages 921 - 9 |